학술논문
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.
Document Type
Article
Author
Source
Subject
*DRUG synergism
*IMATINIB
*CHRONIC myeloid leukemia
*DRUG resistance in cancer cells
*GENETIC mutation
*MITOGEN-activated protein kinases
*PROTEOMICS
*
*
*
*
*
*
Language
ISSN
1552-4450
Abstract
Occurrence of the BCR-ABLT315I gatekeeper mutation is among the most pressing challenges in the therapy of chronic myeloid leukemia (CML). Several BCR-ABL inhibitors have multiple targets and pleiotropic effects that could be exploited for their synergistic potential. Testing combinations of such kinase inhibitors identified a strong synergy between danusertib and bosutinib that exclusively affected CML cells harboring BCR-ABLT315I. To elucidate the underlying mechanisms, we applied a systems-level approach comprising phosphoproteomics, transcriptomics and chemical proteomics. Data integration revealed that both compounds targeted Mapk pathways downstream of BCR-ABL, resulting in impaired activity of c-Myc. Using pharmacological validation, we assessed that the relative contributions of danusertib and bosutinib could be mimicked individually by Mapk inhibitors and collectively by downregulation of c-Myc through Brd4 inhibition. Thus, integration of genome- and proteome-wide technologies enabled the elucidation of the mechanism by which a new drug synergy targets the dependency of BCR-ABLT315I CML cells on c-Myc through nonobvious off targets. [ABSTRACT FROM AUTHOR]